Deepening underlying synthetic biology capabilities and reinforcing proprietary intellectual property barriers! Recently, Shenzhen Hygieia Biotech Co., Ltd. was officially granted an invention patent by the National Intellectual Property Administration (CNIPA).
This granted patent focuses on high-efficiency enzyme expression and a green NMNH biomanufacturing system. By optimizing gene expression regulatory elements, it achieves high-level expression of glucose dehydrogenase (GDH) and establishes a stable, high-yield biosynthetic pathway for NMNH.
As a potent next-generation precursor to NAD+, NMNH holds vast application potential in healthy aging, mitochondrial homeostasis maintenance, oxidative stress regulation, and DNA damage repair. Historically, cost-effective and scalable biomanufacturing has been the core bottleneck hindering the industrial commercialization of NMNH.
Relying on its proprietary synthetic biology platform, Hygieia Biotech continuously tackles key challenges in biocatalysis and enzyme engineering. This patent milestone marks a breakthrough in the company’s reduced nicotinamide nucleotide portfolio, further solidifying our proprietary R&D and green biomanufacturing technology matrix.
Technical Analysis: Hygieia Biotech’s NMNH Biosynthesis & Manufacturing
NMNH (Reduced β-Nicotinamide Mononucleotide), as a next-generation potent NAD⁺ precursor, elevates intracellular NAD(H) levels faster and more effectively than standard NMN at equivalent dosages, serving as a critical focus in cellular repair, metabolic regulation, and longevity intervention[1][2].
- Chemical Reduction Methods: Rely on toxic reducing agents, generate isomeric impurities, and face high purification costs alongside substantial environmental compliance pressure;
- Conventional Enzymatic Routes: Suffer from low glucose dehydrogenase (GDH) expression efficiency, inadequate enzyme yield in engineered strains, and limited substrate conversion, leading to high commercial-scale costs[3];
- Translation Bottlenecks: Native ribosome binding site (RBS) sequences in prokaryotic expression systems exhibit low efficiency, significantly limiting key catalytic enzyme yield[4].
Hygieia’s patented innovation begins with the rational engineering of underlying gene expression elements, bridging the end-to-end pathway from “Genetic Element Engineering → Engineered Strain Construction → Whole-Cell Catalytic Synthesis of NMNH,” building an eco-friendly biosynthetic route with fully proprietary IP.
Key Differentiation: Rational de novo design of novel RBS regulatory elements (Sequences SEQ ID NO.1–10).
The RBS is a crucial element for translation initiation that directly dictates protein translation efficiency[4][5]. Through precise sequence optimization, Hygieia constructed highly efficient RBS elements paired with targeted promoters in a GDH expression vector, drastically boosting GDH expression in E. coli and overcoming the primary bottleneck in enzymatic NMNH production.
Complete NMNH Biomanufacturing Process
STEP 01
Recombinant Expression Vector Construction
Incorporate proprietary, rationally designed and optimized RBS elements;
Vector Architecture: Promoter + Optimized RBS Element + Glucose Dehydrogenase (GDH) Coding Gene;
Construct recombinant plasmids and transform into E. coli host strains to obtain high-performance GDH engineered strains.
STEP 02
Fermentation & Induced GDH Expression
Submerged liquid fermentation of recombinant E. coli strains;
Induce target gene expression to achieve high intracellular accumulation of catalytically active GDH;
Harvest biomass via post-fermentation centrifugation to yield whole-cell biocatalysts (applicable directly as whole cells or via cell disruption to obtain crude enzyme solution).
STEP 03
Enzymatic Biocatalysis for NMNH Synthesis
Reaction Substrates: β-Nicotinamide Mononucleotide (NMN) + D-Glucose
Biocatalyst: In-house manufactured GDH whole-cell catalyst
Catalytic Mechanism: GDH utilizes D-glucose as a hydrogen donor to reduce oxidized NMN into NMNH, concurrently oxidizing glucose into gluconic acid. Leveraging endogenous cofactor pools or in situ regeneration mechanisms, it achieves seamless cofactor recycling without requiring costly external cofactor supplementation[6].
Reaction Conditions: Mild aqueous phase, ambient temperature and pressure, neutral to slightly alkaline pH, 100% organic solvent-free.
NMN + D-Glucose —(GDH)—→ NMNH + D-Gluconic Acid
STEP 04
Product Separation & Downstream Purification
Upon completion of biocatalysis, biomass is removed via microfiltration to obtain crude NMNH solution;
Sequential processing through ultrafiltration, ion-exchange chromatography, nanofiltration concentration, and lyophilization yields high-purity solid NMNH raw material.
Key Technological Advantages vs. Conventional Solutions
Independent of commercial vector elements, our proprietary RBS sequences resolve foreign gene translation bottlenecks, yielding GDH expression levels significantly higher than standard systems;
Aqueous enzymatic catalysis eliminates toxic reducing agents, yields benign single by-products (gluconate), minimizes isomeric impurities, and easily meets premium raw material standards;
Seamlessly compatible with existing fermentation and biocatalysis infrastructure, empowering continuous GDH mutant evolution via our Zymevolver® platform to continually raise conversion rates.
This patent achieves an integrated intellectual property portfolio encompassing “RBS Regulatory Elements — GDH Engineered Strains — NMNH Biosynthesis.” It establishes that Hygieia Biotech possesses the complete synthetic biology value chain from genetic design to final active ingredient, reinforcing our competitive edge in the NAD⁺ precursor landscape and supporting commercial-scale supply and ODM/CDMO customization.
What Does This Patent Mean for Brand R&D and Procurement Teams?
Evaluating the true value of an ingredient manufacturing patent extends beyond acquiring intellectual property credentials. The critical criteria lie in whether the technology seamlessly translates into standardized, scalable production, guarantees consistent batch-to-batch quality, and establishes a resilient, sustainable raw material supply chain.
For brand formulators, R&D heads, and global sourcing directors, this patent delivers multidimensional value across supply security, formulation differentiation, long-term cost optimization, and compliance risk mitigation.
Most market offerings remain concentrated around conventional precursors like NMN and NR. As a reduced nicotinamide nucleotide, NMNH operates via distinct metabolic kinetics and absorption pathways. Brand partners can leverage this technical route to craft novel, differentiated formulas, avoiding commoditization with patent-backed storytelling.
By optimizing RBS elements for high-yield GDH expression, our process drastically lowers energy consumption and by-product generation. For procurement, this mature biocatalytic route unlocks ongoing scale-driven cost reductions; for R&D, it guarantees batch purity consistency and minimizes pilot-scale scale-up variables.
Brands can build credible scientific narratives anchored in upstream patent-protected technology while mitigating third-party IP infringement risks. Verifiable synthesis patents serve as an essential qualification benchmark in rigorous B2B supplier selection.
The foundation of this patent lies in modular genetic element design, enzyme evolution, and biocatalytic platforms. For strategic pipeline planning, this technology expands horizontally to other nicotinamide derivatives, enabling brands to build synergistic active molecule portfolios under one unified platform.
Unlocking the Long-Term Industrial Value of Novel Actives
Intellectual property is the cornerstone of innovation, and industrial scalability is the ultimate test of technological value. This NMNH invention patent grant represents both a milestone in Hygieia’s reduced nucleotide pipeline and an embodiment of our commitment to foundational synthetic biology.
Serving the global health and longevity industry, Hygieia Biotech will continue driving process iteration and scalable delivery of cutting-edge active molecules, providing downstream brands with stable, compliant, and differentiated premium raw materials.
We look forward to collaborating with industry partners worldwide to unlock the full therapeutic and nutraceutical potential of NMNH in healthy aging, driving high-quality industry transformation through upstream innovation.
[1] Yang Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD⁺ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth[J]. Journal of Proteome Research, 2021, 20(5):2596-2606.
[2] Scantlebery A M L, et al. Reduced Versus Oxidized NAD⁺ Precursors Drive Distinct Transcriptomic, Proteomic, and Metabolic Profiles in Hepatocytes[J]. The FASEB Journal, 2026, 40(2).
[3] Chen Y, et al. Modulation of enzyme expression via RBS engineering for redox biocatalysis and cofactor regeneration[J]. ACS Synthetic Biology, 2024,13(8):2145–2156.
[4] Salis H M, Mirsky E A, Voigt C A. Automated design of synthetic ribosome binding sites to control protein expression[J]. Nature Biotechnology, 2009, 27(10):946-950.
[5] Wang L, et al. RBS library optimization enhances glucose dehydrogenase production for NAD(P)H biomanufacturing[J]. Applied and Environmental Microbiology, 2025.
[6] Black W B, et al. Engineering a nicotinamide mononucleotide redox cofactor system for biocatalysis[J]. Nature Catalysis, 2019, 2(11): 974–984.
HYGIEIA BIOTECH
Hygieia Biotech leverages its proprietary Zymevolver® strain engineering and enzyme directed evolution platform to semi-rationally design next-generation, high-efficacy longevity active molecules. We have constructed a comprehensive portfolio centered around cellular health, supported by an integrated R&D and production complex spanning nearly 10,000 m², including a 1,500 m² advanced R&D pilot center and an 8,000 m² cGMP-compliant manufacturing facility.
Our scientific team has instituted a robust three-tier safety validation framework encompassing toxicological evaluation, preclinical animal models, and human randomized clinical trials (RCTs), rigorously authenticating product efficacy, safety, and bioequivalence across every stage.
Holding 10+ core invention patents, Hygieia serves as a primary drafter for group standards of NMN, L-Ergothioneine, and α-Ketoglutaric Acid. Certified under FSSC 22000, HALAL, and KOSHER, Hygieia is recognized as a National High-Tech Enterprise, Specialized & Sophisticated ‘Little Giant’ enterprise, and leading Synthetic Biology Innovation Center.